A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Phase I;To investigate the clinically recommended dose of Sunitinib malate (SU011248)
following multiple oral dosing in the first cycle (4 consecutive weeks and 2 weeks rest) by
reviewing the safety and tolerability.
Phase II;To determine the objective tumor response and the safety of Sunitinib malate
(SU011248) at the clinically recommended dose.